This document provides a summary of Anthony Payne's professional experience and qualifications. It summarizes his experience in sales roles within the pharmaceutical industry, promoting medications to healthcare providers to maximize sales. It also outlines his educational background and professional development activities.

1. ANTHONY PAYNE
607 Birchwood Court
Jefferson, SD 57038
Home: 605.540.0442 matpayne@cableone.net Cell: 712.574.0216
SUMMARY
Accomplished Sales Professional with proven ability to drive territorial growth. A self-motivated
expeditor known for creating and implementing effective targeting strategies to maximize results with
high value customers. Additional strengths in making consultative sales presentations, providing
excellent customer service, and continued industry self education.
PROFESSIONAL EXPERIENCE
GLAXOSMITHKLINE, Research Triangle Park, NC 2008 – 2010
Pharmaceutical Sales Representative
Promoted medications in a sales team environment to practicing physicians and mid-level providers
within an assigned territory that ensured the appropriate use of products to achieve the business
potential of the territory.
• Ranked in the Top 10% Nationally for Lovaza 1st Quarter 2010 goal attainment by building
relationships with medical providers and providing relevant information about the link
between cardiovascular disease and product benefits.
• Assigned to a dormant, under-performing territory in January 2009, developed and executed
a sales strategy which transformed the territory to a ranking of Top 10% nationally in division
portfolio attainment within a year.
• First place rank regionally during the 4th Quarter of 2008 in Total Portfolio Achievement with
a portfolio achievement of 257% of goal, executing on division plan of action in a newly
developed territory after being retained by GlaxoSmithKline in April 2008.
RELIANT PHARMACEUTICALS, Liberty Corner, NJ 2001 – 2008
Pharmaceutical Sales Representative
Ethically promoted medications in a single member territory environment to practicing physicians
and mid-level providers in a variety of assigned territories that ensured the appropriate use of
promoted products to maximize profitability of the territories.
• Developed and executed a plan of action that resulted in a 6th place rank nationally in Total
Portfolio Achievement of the 90 sales professionals that were retained by GlaxoSmithKline
after the purchase and merger of Reliant Pharmaceuticals.
• Awarded additional territory in January 2007 that had been dormant for two years.
Introduced Lovaza with a well defined and executed strategy that led to a Top 1% rank
nationally in Total Prescription Growth in the Primary Care Division during the 4th Quarter
over 3rd Quarter 2007 with 33.69% increase in sales.
• Utilized national Dyna Circ CR branding strategy while incorporating personally customized
execution of this strategy resulting in the Exceptional Sales Achievement in Hypertension
Award in October 2006, and again in May 2007.
• Followed regionally developed portfolio plan of action while maximizing features and benefits
of portfolio products resulting in the Regional Sales Award for the 4th Quarter 2002 and
again for the 2nd Quarter 2004.

2. ANTHONY PAYNE PAGE TWO
CHESTERMAN COMPANY, Sioux City, IA 1991 – 2001
Route Sales Professional
Sales and service of Coca-Cola branded products to accounts on assigned routes to maximize sales
revenue.
• Demonstrated excellence in sales and service to clients resulting in a superior customer
service rating during the 1997 Chesterman Company Customer Survey.
• Utilized company authorized promotional pricing and developed an execution strategy
resulting in a 2nd place rank in the 4th Quarter 1996, Sales Growth Contest with a 24%
increase in total sales.
• Developed an execution plan to convert 7up sales to Sprite sales, resulting in a 2nd place
ranking during the 1995 Sprite Conversion Contest with a 108% conversion rate.
EDUCATION
BS, Business Administration – Marketing, Wayne State College, Wayne, NE
PROFESSIONAL DEVELOPMENT
• Reliant Pharmaceuticals Advanced Sales Training Graduate
• The Essentials of Excellent Customer Service – SkillPath Seminars
• Dale Carnegie Fast-Track Sales Training Course
• Member of Chesterman Company Sales Training Team, 1995 – 2000
• Member of Chesterman Company Safety Committee, 1995 – 2000
PHARMACEUTICAL INDUSTRY SPECIFIC
• FDA Approvals: Rapaflo and Akten (Medscape CME), 2009
• Prostate Cancer Screening and Prevention: A Clinical Update for Primary Care Providers
(Medscape CME), 2008
• Higher Nonfasting Triglycerides Linked With Increased Ischemic Stroke Risk (Medscape CME),
2008
• Omega-3 Rather Than Genetics Is Key to Lack of CHD in Japanese? (Medscape CME), 2008
• Management of Benign Prostatic Hyperplasia Reviewed (Medscape CME), 2008
• Emerging Data in the Treatment of Mixed Dyslipidemia (Medscape CME), 2008
• Understanding Triglycerides: Beyond LDL Cholesterol (Medscape CME), 2007
• New Analysis Uncovers Relationship Between Low LDL Cholesterol Levels and Cancer
(Medscape CME), 2007
• Nonfasting Triglyceride Levels Associated With an Increased Risk for Cardiovascular Disease
(Medscape CME), 2007
• Fish Oil Added to Statin Therapy Reduces Risk For Major Coronary Events (Medscape CME),
2007
• LDL-C -- How Low Should You Go? (Medscape CME), 2007
• Fish Oil May Not Reduce Risk of Ventricular Tachycardia or Ventricular Fibrillation in Patients
With an Implantable Cardioverter Defibrillator (Medscape CME), 2006
• New Therapies and Multiple Targets: Moving Beyond Low-Density Lipoprotein Cholesterol in the
Management of Cardiovascular Risk (Medscape CME), 2005

3. ANTHONY PAYNE PAGE THREE
PHARMACEUTICAL INDUSTRY SPECIFIC (Continued)
• Rimonabant May Reduce Weight and Cardiovascular Risk Factors (Medscape CME), 2005
• Stop the Progression: New Approaches to Early Aggressive Combination Therapy (Medscape
CME), 2005
• Rosuvastatin May Be More Closely Associated With Toxicity Than Are Other Statins (Medscape
CME), 2005
• Reliant Pharmaceuticals District Representative for Regional Scientific Committee, 2005
• Good Morning Diabetes: Building a New Framework for Combination Therapy (Medscape CME),
2004
• Sculpting New Treatment Strategies for High-Risk Patients With Dyslipidemia (Medscape CME),
2004
• W.A.T.C.H.: Women's Agenda Targeting Cholesterol in Heart Disease (Medscape CME), 2004
• NCEP Updates ATP III Guidelines With Evidence From Recent Statin Trials (Medscape CME),
2004